Contact
Please use this form to send email to PR contact of this press release:
Immix Biopharma Further Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2
TO:
Please use this form to send email to PR contact of this press release:
Immix Biopharma Further Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2
TO: